|
|
|||
|
|||
|
|
|||
|
supplement with namenda |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
supplement with namenda Generic Name: memantine HCl Date of Approval: Manufacturer: Treatment for: The U.S supplement with namenda. Food and Drug Administration (FDA) has approved Namenda (memantineHCl) for the treatment of moderate to severe Alzheimer's disease supplement with namenda. Namenda isthe first NMDA receptor antagonist to be approved for Alzheimer's disease andis also the only therapy approved for the treatment of moderate to severe Alzheimer'sdisease. Namenda's FDA approval is based on the Agency's review of safety and efficacydata from two U.S supplement with namenda. placebo-controlled Phase III clinical trials and an earliertrial conducted among nursing home patients in Europe supplement with namenda. Phase III data includeda 28-week monotherapy study of 252 patients published earlier this year in theNew England Journal of Medicine and a six-month, 401-patient study of Namendawhen used together with an ongoing regimen of the commonly used Alzheimer'sagent, donepezil supplement with namenda. In trials, patients treated with Namenda scored higher onmeasures of cognition, daily function, and/or global performance supplement with namenda. This developmentprogram for memantine was a joint effort between Forest and its licensor, MerzPharmaceuticals, who obtained centralized approval for memantine in the EuropeanUnion in 2002 supplement with namenda. Merz Pharmaceuticals is a specialty pharmaceutical company dedicatedto research and development in the fields of neurology and psychiatry. In clinical trials, Namenda has been safe and well tolerated supplement with namenda. The most commonadverse events observed in clinical trials are dizziness, headache, constipation,and confusion supplement with namenda. Once available in pharmacies, Namenda will be administered orallyat a recommended dose of 10 mg BID following a four-week titration. Alzheimer's is a progressive disease of the brain and it is the most commontype of dementia supplement with namenda. The term dementia is used to describe the progressive lossof cognitive, intellectual, or functional abilities supplement with namenda. Published reports projectthat by 2010 more than 5.1 million people in the United States will have Alzheimer'sdisease supplement with namenda. Currently, all Alzheimer's medications approved in the United Statesbelong to a class of agents called acetylcholinesterase inhibitors, which areindicated for patients with mild to moderate symptoms of the disease supplement with namenda. Namendais the only approved therapy in the United States for moderate to severe Alzheimer'sdisease.
Namenda (memantine HCl) is the first of a new class of medications for Alzheimer'sdisease with a mechanism of action distinct from currently available drugs supplement with namenda. Namenda is a low to moderate affinity NMDA (N-methyl-D- aspartate) receptorantagonist supplement with namenda. It is thought that overexcitation of NMDA receptors by the neurotransmitterglutamate may play a role in Alzheimer's disease since glutamate plays an integralrole in the neural pathways associated with learning and memory supplement with namenda. The excitotoxicityproduced by abnormal levels of glutamate is thought to be responsible for neuronalcell dysfunction and the eventual cell death observed in Alzheimer's disease supplement with namenda. Namenda is thought to selectively block the excitotoxic effects associated withabnormal transmission of glutamate, while allowing for the physiological transmissionassociated with normal cell functioning. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ssupplement with namenda suupplement with namenda suppplement with namenda suppplement with namenda suppllement with namenda suppleement with namenda supplemment with namenda supplemeent with namenda supplemennt with namenda supplementt with namenda supplement with namenda supplement wwith namenda supplement wiith namenda supplement witth namenda supplement withh namenda supplement with namenda supplement with nnamenda supplement with naamenda supplement with nammenda supplement with nameenda supplement with namennda supplement with namendda supplement with namendaa upplement with namenda spplement with namenda suplement with namenda suplement with namenda suppement with namenda supplment with namenda suppleent with namenda supplemnt with namenda supplemet with namenda supplemen with namenda supplementwith namenda supplement ith namenda supplement wth namenda supplement wih namenda supplement wit namenda supplement withnamenda supplement with amenda supplement with nmenda supplement with naenda supplement with namnda supplement with nameda supplement with namena supplement with namend s upplement with namenda su pplement with namenda sup plement with namenda supp lement with namenda suppl ement with namenda supple ment with namenda supplem ent with namenda suppleme nt with namenda supplemen t with namenda supplement with namenda supplement with namenda supplement w ith namenda supplement wi th namenda supplement wit h namenda supplement with namenda supplement with namenda supplement with n amenda supplement with na menda supplement with nam enda supplement with name nda supplement with namen da supplement with namend a supplement with namenda uspplement with namenda spuplement with namenda supplement with namenda suplpement with namenda suppelment with namenda supplmeent with namenda suppleemnt with namenda supplemnet with namenda supplemetn with namenda supplemen twith namenda supplementw ith namenda supplement iwth namenda supplement wtih namenda supplement wiht namenda supplement wit hnamenda supplement withn amenda supplement with anmenda supplement with nmaenda supplement with naemnda supplement with namneda supplement with namedna supplement with namenad asupplement with namenda thesupplement with namenda supplement with namenda | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
